New hope for tough lung cancers: trial tests combo to reboot immune attack
NCT ID NCT05553834
Summary
This study is testing whether combining two existing drugs—alirocumab and cemiplimab—can help control advanced lung cancer that has gotten worse after initial immunotherapy. It will involve about 60 adults whose cancer has spread and who have already tried and stopped responding to a similar type of immunotherapy drug. The main goal is to see if this new combination can shrink tumors and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
Durham, North Carolina, 27705, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.